Association of the rs1611115 polymorphism in DBH gene with Parkinson’s disease: a meta-analysis
A meta-analysis was performed to assess the association between the dopamine beta-hydroxylase (DBH) rs1611115 genetic polymorphism and Parkinson’s disease (PD). A comprehensive search was conducted to identify all case–control or cohort studies. The fixed or random effect-pooled measure was selected on the basis of a homogeneity test among studies. Heterogeneity among studies was evaluated using the I2. We performed sensitivity analyses to evaluate the robustness of the results. Publication bias was estimated using Egger’s linear regression test. Five case–control studies corresponded to the inclusion criteria comprising 3926 patients and 3542 controls which were included in the present meta-analysis. Our meta-analysis showed no significant association between DBH rs1611115 genetic polymorphism and risk of PD in the codominant (REM, OR = 1.017, 95%CI = 0.854–1.210), dominant (REM, OR = 0.989, 95%CI = 0.826–1.185), and recessive (REM, OR = 1.007, 95%CI = 0.657–1.542) models. Moreover, in the subgroup analysis based on region (Asia and Europe), no significant associations were observed in Asia or Europe. This meta-analysis suggests that the DBH rs1611115 genetic polymorphism might not be associated with PD.
Keywordsrs1611115 DBH Polymorphism Meta-analysis Parkinson’s disease
This work was supported by grants from the National Foundation of Natural Science of China (31471114, 31500837, and 31540075), Shandong Provincial Natural Science Foundation (BS2015SW002), Shandong Province Special Foundation for Postdoctoral Innovation (201401006, 201603068), the Department of Shandong Provincial Education (J15LE18), Taishan Scholarship, and Program for New Century Excellent Talents in University.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
- 10.O'Connor DT, Cervenka JH, Stone RA, Levine GL, Parmer RJ, Franco-Bourland RE, Madrazo I, Langlais PJ, Robertson D, Biaggioni I (1994) Dopamine beta-hydroxylase immunoreactivity in human cerebrospinal fluid: properties, relationship to central noradrenergic neuronal activity and variation in Parkinson’s disease and congenital dopamine beta-hydroxylase deficiency. Clin Sci (London, England : 1979) 86:149–158CrossRefGoogle Scholar
- 11.Zabetian CP, Anderson GM, Buxbaum SG, Elston RC, Ichinose H, Nagatsu T, Kim KS, Kim CH, Malison RT, Gelernter J, Cubells JF (2001) A quantitative-trait analysis of human plasma-dopamine beta-hydroxylase activity: evidence for a major functional polymorphism at the DBH locus. Am J Hum Genet 68:515–522CrossRefPubMedPubMedCentralGoogle Scholar
- 12.Zabetian CP, Buxbaum SG, Elston RC, Kohnke MD, Anderson GM, Gelernter J et al (2003) The structure of linkage disequilibrium at the DBH locus strongly influences the magnitude of association between diallelic markers and plasma dopamine beta-hydroxylase activity. Am J Hum Genet 72:1389–1400CrossRefPubMedPubMedCentralGoogle Scholar
- 16.Healy DG, Abou-Sleiman PM, Ozawa T, Lees AJ, Bhatia K, Ahmadi KR, Wullner U, Berciano J, Moller JC, Kamm C, Burk K, Barrone P, Tolosa E, Quinn N, Goldstein DB, Wood NW (2004) A functional polymorphism regulating dopamine beta-hydroxylase influences against Parkinson’s disease. Ann Neurol 55:443–446CrossRefPubMedGoogle Scholar
- 26.Mittal S, Bjornevik K (2017) beta2-Adrenoreceptor is a regulator of the alpha-synuclein gene driving risk of Parkinson’s disease. 357:891–898Google Scholar